Ka India kam chibynta wow pynkhlan yei bor yaleh pyrchah yaka khlam COVID-19, nadooh u Naisan, 2020 da thung ko yaka Task Force wa khlieh da u Principal Scientific Advisor yow pynchlur yei thooh bniah wa i chna ya i dawa yada na u COVID-19 wei ha u Naisaphra 2020, da chna sa ya ka Expert Group kawa khlieh da u dkhot ka NITI yow yarap yei e dawai tika heiwa hapoh ka India da em ar tylli ki dawai tika kiwa pynmih pyn hapoh ka ri hi.
Katni da em 2 tylli ki dawai tika namo ki Vaccine kiwa da pynemkaam hapoh ka ri kitæ u Covaxin wa pynmih daka Bharat Biotech International Limited (BBIL) wa u Covishield wa pynmih daka Serum Institute of India (SII), kiwa da yoh bor wow pynemkaam lyngba ka Emergency Use Authorization (EUA) ka National Regulator (Drugs Controller General of India).
Kamtæ da pyrkhat wa da emkaam chooh chooh ya kini ki dawai tika, heiwa haka yalang wa 23 yong ka National Expert Group on Vaccine Administration for COVID-19 (NEGVAC) kawa pynman haka 11 tarik uni u bnai wa chongknor da u Dr. V K Paul, Member (Health), Niti Aayog. Da tyrwa wa ki dawai yada na u COVID-19 kiwa da chna da kiwi ki reh leh kiwa da dep yoh bor wow pynemkaam daka USFDA, EMA, UK MHRA, PMDA Japan lane kiwa da em pyrtuid haka WHO (Emergency Use Listing) ye ki leh wow yoh bor wow pynemkaam ha India, deiwa pyrchang chwa ya ki (Local Clinical Trial) katkam ka Second Schedule ka New Drugs & Clinical Trials Rules 2019.
Chooh chooh ya ki nyngkong ki 100 ngut kiwa yoh ya kini ki dawai tika daw paitbniah ya ki 7 sngi chwa wow pynemkaam ya i dawa hapoh waroh kawi ka ri.
Neiliang ka sorkar India leh da pdiang ko ya ini i tyrwa ka NEGVAC.
Neiliang ka sorkar da ong ko leh wa ini daw yarap ko yaka ri wow yoh chiboon i dawai yow pyndap yeiwa duna u pynemkaam hapoh ka ri.
